Evidence map›Paper›PMID 35885666›Full record

ReviewDiagnostics (Basel, Switzerland)2022

Personalized Dosimetry in the Context of Radioiodine Therapy for Differentiated Thyroid Cancer.

Massimiliano Pacilio, Miriam Conte, Viviana Frantellizzi, Maria Silvia De Feo, Antonio Rosario Pisani, Andrea Marongiu, Susanna Nuvoli, Giuseppe Rubini, Angela Spanu, Giuseppe De Vincentis

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Dose-activity relationship in [Annals of nuclear medicine · 2026
    Article
  3. Review
  4. Article
  5. Observational
  6. Traditional Chinese Medicine Treatment of Thyroid Cancer: A Review.International journal of general medicine · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Massimiliano PacilioMedical Physics Department, "Policlinico Umberto I" University Hospital, 00161 Rome, Italy.ORCID 0000-0002-2817-6927
Miriam ConteDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Viviana FrantellizziDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-3497-4236
Maria Silvia De FeoDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Antonio Rosario PisaniSection of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy.
Andrea MarongiuUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Susanna NuvoliUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.
Giuseppe RubiniSection of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, 70121 Bari, Italy.ORCID 0000-0003-1972-3308
Angela SpanuUnit of Nuclear Medicine, Department of Medical, Surgical and Experimental Sciences, University of Sassari, 07100 Sassari, Italy.ORCID 0000-0001-5753-399X
Giuseppe De VincentisDepartment of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza University of Rome, 00161 Rome, Italy.ORCID 0000-0003-4690-1528
Sapienza University of Rome · ITUniversity of Sassari · ITUniversity of Bari Aldo Moro · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most frequent thyroid cancer is Differentiated Thyroid Cancer (DTC) representing more than 95% of cases. A suitable choice for the treatment of DTC is the systemic administration of 131-sodium or potassium iodide. It is an effective tool used for the irradiation of thyroid remnants, microscopic DTC, other nonresectable or incompletely resectable DTC, or all the cited purposes. Dosimetry represents a valid tool that permits a tailored therapy to be obtained, sparing healthy tissue and so minimizing potential damages to at-risk organs. Absorbed dose represents a reliable indicator of biological response due to its correlation to tissue irradiation effects. The present paper aims to focus attention on iodine therapy for DTC treatment and has developed due to the urgent need for standardization in procedures, since no unique approaches are available. This review aims to summarize new proposals for a dosimetry-based therapy and so explore new alternatives that could provide the possibility to achieve more tailored therapies, minimizing the possible side effects of radioiodine therapy for Differentiated Thyroid Cancer.

Indexed as

absorbed doseDifferentiated Thyroid Cancerpersonalized dosimetryradioiodine therapy

Identifiers

PMID35885666
PMCPMC9320760
OpenAlexW4286492780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.